Active immunisation against varicella infection
Adult: Each 0.5 mL contains live, attenuated varicella-zoster virus (VZV) Oka/Merck strain ≥103.3 plaque-forming units (PFU), or ≥1,350 PFU: 0.5 mL for 2 doses via deep SC or IM inj, doses are given 4-8 weeks apart.
Child: 9 months to 12 years (or 1-12 years, based on product used) 0.5 mL for 2 doses via deep SC or IM inj; the 2nd dose is to be given after an interval of at least 3 months (or 6 months based on national recommendations); ≥13 years Same as adult dose.
Child: 9 months to 12 years (or 1-12 years, based on product used) 0.5 mL for 2 doses via deep SC or IM inj; the 2nd dose is to be given after an interval of at least 3 months (or 6 months based on national recommendations); ≥13 years Same as adult dose.
Subcutaneous
Prevention of herpes zoster, Prevention of herpes zoster-related postherpetic neuralgia
Adult: Each 0.65 mL contains live, attenuated VZV Oka/Merck strain ≥19,400 PFU: ≥50 years 0.65 mL for 1 dose.